Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles by unknown
Nanotechnology and cancer: improving 
real‑time monitoring and staging of bladder 
cancer with multimodal mesoporous silica 
nanoparticles
Sean K Sweeney1,2, Yi Luo3, Michael A O’Donnell4 and Jose Assouline1,2*
Abstract 
Background: Despite being one of the most common cancers, bladder cancer is 
largely inefficiently and inaccurately staged and monitored. Current imaging methods 
detect cancer only when it has reached “visible” size and has significantly disrupted 
the structure of the organ. By that time, thousands of cells will have proliferated and 
perhaps metastasized. Repeated biopsies and scans are necessary to determine the 
effect of therapy on cancer growth. In this report, we describe a novel approach based 
on multimodal nanoparticle contrast agent technology and its application to a preclini-
cal animal model of bladder cancer. The innovation relies on the engineering core of 
mesoporous silica with specific scanning contrast properties and surface modification 
that include fluorescence and magnetic resonance imaging (MRI) contrast. The overall 
dimensions of the nano-device are preset at 80–180 nm, depending on composition 
with a pore size of 2 nm. 
Methods: To facilitate and expedite discoveries, we combined a well-known model of 
bladder cancer and our novel technology. We exposed nanoparticles to MB49 murine 
bladder cancer cells in vitro and found that 70 % of the cells were labeled by nanopar-
ticles as measured by flow cytometry. The in vivo mouse model for bladder cancer is 
particularly well suited for T1- and T2-weighted MRI. 
Results: Under our experimental conditions, we demonstrate that the nanoparticles 
considerably improve tumor definition in terms of volumetric, intensity and struc-
tural characteristics. Important bladder tumor parameters can be ascertained, non-
invasively, repetitively, and with great accuracy. Furthermore, since the particles are 
not biodegradable, repetitive injection is not required. This feature allows follow-up 
diagnostic evaluations during cancer treatment. Changes in MRI signals show that 
in situ uptake of free particles has predilection to tumor cells relative to normal bladder 
epithelium. The particle distribution within the tumors was corroborated by fluorescent 
microscopy of sections of excised bladders. In addition, MRI imaging revealed fibrous 
finger-like projections into the tumors where particles insinuated themselves deeply. 
This morphological characteristic was confirmed by fluorescence microscopy. 
Conclusions: These findings may present new options for therapeutic intervention. 
Ultimately, the combination of real-time and repeated MRI evaluation of the tumors 
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enhanced by nanoparticle contrast may have the potential for translation into human 
clinical studies for tumor staging, therapeutic monitoring, and drug delivery.
Keywords: Mesoporous silica nanoparticles, Transitional cell carcinoma, Bladder, 
Magnetic resonance imaging, Cystoscopy, Mouse orthotopic tumor model
Background
Transitional Cell Carcinoma (TCC) of the bladder is the fifth most common malignancy 
in the United States (Siegel et al. 2015). Although the majority of human bladder can-
cer is superficial at the time of detection, the recurrence rate and the risk of progres-
sion to advanced disease are high (Hall et al. 2007; Kaufman et al. 2009; Faba et al. 2012; 
Nargund et al. 2012). Currently, the most common screening method is cystoscopy (Liu 
et al. 2012), which includes white light as well as fluorescent or narrow band cystoscopy 
(Kriegmair et al. 1994; Filbeck et al. 2002; Joudi and Konety 2004). The fluorescent and 
narrow band methods aim to highlight or differentiate the tumor from normal blad-
der epithelium wall using broad range/non-specific fluorescent dyes or stains (Filbeck 
et  al. 2002; Joudi and Konety 2004). These generic labeling methods are not aimed at 
any particular molecule, but rather colorize the entire bladder with the hope that some 
differential labeling may occur. Macroscopic tumors can be seen with these methods, 
but smaller lesions may be missed (Zaak et al. 2005; Grossman et al. 2006). In addition, 
suspicious smaller lesions need biopsy for cancer staging, as cystoscopy alone remains 
insufficient (Cheng et al. 2000, 2009; Mitra et al. 2012).
The development of diagnostic tools for TCC has been slowed by the lack of an opti-
mal animal model for the disease, due to the anatomical inaccessibility and the relative 
lack of molecular and bioinformatics data on the genetic diversity of the specific tumors. 
A variety of experimental models have been tested with mixed success, including mice 
(Chan et al. 2009; Zhang et al. 2015), rabbits (Nemoto et al. 1981), and primates (Cozzi 
et al. 2001). The current standard is a mouse orthotopic tumor model in which a known 
TCC cell line (MB49) is implanted following chemical disruption of the normal epithe-
lium (Soloway et  al. 1973; Bockholt et  al. 2012; Newton et  al. 2014). This cell line has 
similar features and replicates the pathobiology of human homologues (Luo et al. 2004). 
Although the presence of reporter genes has allowed for some measurements of non-
invasive real-time tumor growth, no methods have been described capable of providing 
3-dimensional details of growth, including heterogeneities within the tumor, in real time.
In addition to diagnostic tools, therapeutic options for TCC are limited by anatomi-
cal challenges. After initial resection, many patients undergo bacillus Calmette-Guerin 
(BCG) immunotherapy; however, the recurrence rate for BCG is up to 50 % (Hall et al. 
2007; Faba et  al. 2012). Furthermore, many patients cannot complete the therapy due 
to the risks of sepsis and other side effects (Lamm et al. 2000; Brausi et al. 2014). Thus, 
groups have attempted to package an attenuated form of the BCG cell wall skeleton into 
nanoparticles to more safely induce an immune response, with mixed results (Ochiai 
et al. 1983; Nakamura et al. 2014). Many other forms of nanoparticles are used as carri-
ers of chemotherapeutics; (Connolly et al. 2012; Huang et al. 2012) these, however, often 
cannot be visualized/detected and have poor retention in the bladder. Very few examples 
exist of chemical agents that can be used both for detection and therapeutic solutions. 
Page 3 of 18Sweeney et al. Cancer Nano  (2016) 7:3 
For example, radioactive agents produce quality PET/SPECT images, (Hoilund-Carlsen 
et  al. 2014; Bouchelouche and Choyke 2015) but have short half-lives, necessitating 
repeated doses for longitudinal studies, further increasing the patients’ exposure to ion-
izing radiation. Thus, there is a need for an advanced compound which would provide a 
good image using lowered-cost equipment (ultrasound, MRI), with no ionizing radiation 
and with good retention in the bladder for follow-up growth evaluation. The develop-
ment of a single agent capable of providing sequentially valuable information from MRI 
as well as ultrasound contrast [image-guided surgical techniques (Nyland et  al. 2002; 
Gkritsios et al. 2014)] would be highly desirable.
Mesoporous silica nanoparticles (MSNs) are often studied as vehicles for drug delivery 
due to their large ratios of pore volume and surface area to weight relative to other nano-
materials (Giri et al. 2005; Gruenhagen et al. 2005; Slowing et al. 2007; Chen et al. 2010; 
Benezra et al. 2011). Once injected, MSNs are bioinert, non-toxic and well-tolerated at 
clinically relevant concentrations (Slowing et al. 2006; Lu et al. 2008, 2010), unlike bio-
degradable polymers that can generate toxic byproducts (Athanasiou et al. 1996; Semete 
et  al. 2010), or nanomaterials with reactive elements such as quantum dots (Kirchner 
et al. 2005; Liu et al. 2014). In addition, the use of MSNs in imaging applications is an 
area of active research. In particular, MSN are used to label and track cells through func-
tionalization with fluorophores (Giri et al. 2005; Chen et al. 2010; Benezra et al. 2011), 
paramagnetic materials for magnetic resonance imaging (MRI) (Chen et al. 2010; Hsiao 
et  al. 2008; Larsen et  al. 2009), or electron dense materials for computed tomography 
(CT) (Chen et al. 2010; Luo et al. 2011).
Here, we describe the application of a novel MSN tool for noninvasive and longitu-
dinal tracking of bladder cancer, using an established in vivo mouse model for the dis-
ease. Murine bladder cancer cells (MB49) were found to take up the MSN in vitro; in the 
mouse bladder, the MSN were taken up preferentially by tumor cells more readily than 
healthy bladder epithelium. The MSN were further functionalized with a peptide found 
to bind specifically to bladder cancer cells, thus improving specificity. The MSN facili-
tated the use of tumor imaging/staging in vivo using MRI, and ex vivo using fluorescent 
microscopy. This study presents the potential of these MSN to improve tumor visualiza-
tion and staging, thereby improving patient outcomes.
Methods
Reagents
Gadolinium (III) chloride hexahydrate (GdCl3·6H2O), cetyltrimethylammonium bro-
mide (CTAB, CH3(CH2)15N(CH3)3Br), diethylene glycol, tetraethoxysilane (TEOS), and 
(3-aminopropyl)trimethoxysilane (APTMS) were purchased from Alfa Aesar (Ward Hill, 
MA). Sodium hydroxide (NaOH) was purchased from VWR (Radnor, PA). Methanol, 
dimethyl sulfoxide (DMSO), and toluene were purchased from Fisher Scientific (Pitts-
burgh, PA). Tetramethylrhodamine isothiocyanate (TRITC) was purchased from Sigma-
Aldrich (St. Louis, MO). 2-[Methoxy(polyethyleneoxy)propyl]trimethoxysilane was 
purchased from Gelest (Morrisville, PA). Dulbecco’s modified eagle medium (DMEM), 
Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), and 
penicillin–streptomycin (pen-strep) were purchased from Life Technologies (Grand 
Island, NY).
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Particle synthesis/characterization
First, a gadolinium oxide colloid was obtained following the previously reported synthesis 
(Bridot et al. 2007): GdCl3·6H2O (11.53 g) was dissolved in 200 mL of diethylene glycol at 
60 °C overnight under vigorous stirring. Aqueous NaOH (7.5 mL, 3 M) was added and the 
solution was heated at 140 °C for 1 h and then at 180 °C for 4 h. The obtained transparent 
colloid of gadolinium oxide nanoparticles was stored at room temperature. CTAB (1.0 g, 
2.745 mmol) was dissolved in nanopure water (480 g, 26.67 mol), followed by the addi-
tion of NaOH solution (2.0 M, 3.5 mL, 7.0 mmol). The mixture was heated to 80 °C for 
1 h. To this clear solution, TEOS (4.7 g, 22.56 mmol) was added drop wise, followed by 
immediate addition of 1 mL of the gadolinium oxide colloid. The reaction was stirred vig-
orously at 80 °C for 2 h, then the CTAB surfactant was removed by Soxhlet extraction with 
methanol for 24 h and then dried under vacuum to obtain gadolinium oxide functional-
ized mesoporous silica nanoparticles (Gd2O3–MSN). Next, TRITC (5.7 mg, 0.0128 mmol) 
was reacted with APTMS (2.2345 μL, 0.0128 mmol) in DMSO for 2 h, and TRITC–Gd2O–
MSN was prepared by grafting 0.05 mL of the resulting product on the previously syn-
thesized Gd2O3–MSN (100 mg) in toluene under reflux for 24 h. The resulting solution 
was filtered and the obtained pink solid was washed with copious amount of methanol 
and then dried under vacuum. Finally, the particles were further functionalized with 
poly(ethylene glycol) (PEG) by grafting 2-[Methoxy(polyethyleneoxy)propyl] trimethoxysi-
lane (0.2 mmol) on TRITC–Gd2O3–MSN (100 mg) in toluene under reflux for 24 h. The 
resulting solution was filtered and the obtained pink solid (PEG–TRITC–Gd2O3–MSN) 
was washed with copious amount of methanol and then dried under vacuum.
The materials were characterized by X-ray diffraction, using a Rigaku Ultima IV dif-
fractometer, nitrogen sorption analysis in a Micromeritics ASAP 2020 surface area and 
porosity analyzer using the Brunauer-Emmett-Teller equation to calculate surface area 
and pore volume and the Barrett-Joyner-Halenda equation to calculate the pore size dis-
tribution. Dynamic light scattering (DLS) was used to obtain particle size distribution 
and zeta potential data, using the Malvern Zetasizer Nano ZS instrument. The materials 
were also visualized by transmission electron microscopy (TEM) by supporting samples 
on copper grids in a Tecnai G2 F20 microscope operating at 200 kV.
Cell culture/labeling
Murine TCC cell line MB49 (Summerhayes and Franks 1979) and human TCC cell line 
T24 (Bubenik et al. 1973) are well-established; here, MB49 cells transfected with either 
green fluorescent protein (GFP) or luciferase (luc) reporter genes, and normal T24 cells 
were cultured in RPMI 1640 medium supplemented with 10 % FBS and pen-strep. Cells 
near confluence on tissue culture plastic were exposed to PEG–TRITC–Gd2O3–MSN 
at a concentration of 100 μg/mL for 16 h. Flow cytometry was used to measure the pro-
portion of labeled MB49-GFP+ cells, while fluorescent microscopy was used to evaluate 
labeling on T24 cells. Prior to in vivo experiments, labeled and non-labeled cells were 
counted and the viability measured using trypan blue exclusion dye.
In vivo tumor implantation
All procedures were performed according to NIH guidelines and previously approved by 
the Institutional Animal Care and Use Committee (IACUC). Intravesicular instillation of 
Page 5 of 18Sweeney et al. Cancer Nano  (2016) 7:3 
tumor cells was performed according to previously described methods (Luo et al. 2004). 
Female C57Bl/6 mice were anesthetized with a ketamine/xylazine mixture. The bladder 
was chemically burned by instillation of 5 μL 0.2 M silver nitrate, followed by rinsing with 
100 μL phosphate buffered saline (PBS). A 50 μL suspension containing 5 × 105 MB49-
Luc+ cells in 50 % normal mouse serum was instilled into the bladder and retained for 1 h 
by catheter exclusion. Additional boluses of 1 × 105 tumor cells were injected subcutane-
ously in the left and right flank. In initial experiments designed to determine maximum 
signal, cells were labeled with MSN prior to instillation; in later studies designed to be 
more clinically relevant, the tumor was established prior to instillation of free MSN par-
ticles (1  mg MSN/50  μL PBS). Negative control mice were instilled with sham (saline) 
injections, followed by instillation of free MSN following the same timing as tumor mice.
Imaging/image processing
Images were acquired 24 h after instillation of particles to allow for the elimination of 
free particles through urination. From 1–8 days following tumor implantation, in vivo 
fluorescence and luminescence were measured using the IVIS 200 with appropri-
ate settings for detection of GFP, TRITC, and luciferase activity following intraperi-
toneal injection of 1.5 mg luciferin. MRI scans were acquired using the Unity/INOVA 
4.7 T small animal scanner (Varian, Palo Alto, CA) with a 25-mm gradient RF coil and 
fast spin echo multislice (fsems) sequences with T1- or T2-weighting (T1-weighted 
scans: TR  =  800  ms, TE  =  15  ms, echo train length  =  8, number of averages  =  10; 
T2-weighted scans: TR = 2000 ms, TE = 15 ms, echo train length = 8, number of aver-
ages = 10). Typical image dimensions are 512 × 512 with 30 slices and a voxel size of 
0.068 × 0.068 × 0.4 mm. Scans were saved as DICOM image stacks, which were con-
verted to NIFTI format and preprocessed using a MATLAB routine developed in the 
lab, following a method of background removal Salvado et al. (2006a, b) and interpola-
tion by reverse diffusion Salvado et al. (2006a, b). Using the free medical image process-
ing software MIPAV, scans were normalized to one another by assigning a value of 1000 
to the average intensity of fat adjacent to the kidneys, with all other values linearly inter-
polated between 0 and 1000. Volumes of interest (VOIs) were either manually drawn or 
semi-automatically selected using the “levelset VOI” tool in MIPAV.
Histopathology and statistical analyses
Following the MRI scans, mice were euthanized by CO2 inhalation. The bladders were 
excised, embedded in OCT medium, flash frozen in liquid nitrogen and sectioned. A por-
tion of the sections were mounted on glass slides without stain for use in fluorescence 
microscopy, while adjacent sections were stained with hematoxylin and eosin for histo-
logical analysis. Fluorescence images were acquired using standardized camera settings 
(Olympus DP70 camera, 1360 × 1024 resolution, and 15 s exposure time), while corre-
sponding bright field images were acquired using the same resolution and the camera’s 
auto-exposure setting with color correction. The average red fluorescence intensity of 
each 10× field was quantified by isolating the red channel and using VOI tools to isolate 
regions of tissue from the background, using the bright field images as a reference for 
identifying the tissue and background. The average fluorescence intensity of each image 
was normalized by dividing it by the average intensity of the background. Comparisons of 
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measurements between groups of mice were made using Student’s unpaired T test with 
an alpha level of 0.05 considered significant. Comparisons of different tumors within the 
same mouse were made using a two one-sided t-test (TOST) (Hong et al. 2015) with a 
significance level of α =  0.05 and a test margin of 0.05 (a unitless value of normalized 
MRI intensity), representing the average smallest difference between two intensities that 
our image processing technicians could discern with the naked eye.
Results and discussion
Particle characterization
We synthesized multifunctional MSN for in vivo imaging of bladder tumors according 
to the schematic (Fig. 1a). By incorporating Gd2O3 into the silica matrix and covalently 
grafting FITC or TRITC onto the particle surface, the MSN is functionalized for fluores-
cent and MRI imaging modalities. Systematic characterization was performed at each 
step in the process of synthesizing the PEG–TRITC–Gd2O3–MSN. Powder XRD analy-
sis confirmed hexagonally arranged mesopores in the diffraction pattern of the Gd2O3–
MSN as evident by the intense d100, and well resolved d110 and d200 peaks characteristic 
for MSN (Fig.  1b). Transmission electron micrographs of the Gd2O3–MSN particles 
showed this pattern as well as uniform size distributions and good dispersibility with lit-
tle aggregation (Fig. 1c–e, inset). Nitrogen sorption analysis of the TRITC–Gd2O3–MSN 
exhibited a Type-IV isotherm, typical of mesoporous materials, with a BET surface area 
of 710 m2g−1. The average pore diameter for TRITC–Gd2O3–MSN by BJH calculation 
is 24  Å. The fully synthesized PEG–TRITC–Gd2O3–MSN was characterized by DLS; 
the median hydrodynamic diameter of the particles was 187.3 nm, with 96.3 % of the 
particles falling within the primary distribution peak, spanning between 90 and 400 nm, 
resulting in a polydispersity index (PDI) of 0.535 (Fig.  1f ). The number of particles 
greater than 400 nm (likely aggregated MSN) is less than 4 % of the total and does not 
have adverse experimental implications on the tagging of bladder tumors. Prior to use 
Fig. 1 Characterization of PEG–TRITC–Gd2O3–MSN. a Schematic showing multifunctional MSN particle 
with Gd2O3 incorporated into silica matrix, and FITC or TRITC grafted onto the silica surface, followed by 
poly(ethylene glycol). b Powder X-ray diffraction patterns of TRITC–Gd2O3–MSN after surfactant removal. The 
intense peak at 2.5 2θ is characteristic of hexagonally arranged pores in MSN. c Transmission electron micro-
graph of synthesized MSN, with higher magnification inset (d), and fully synthesized PEG–TRITC–Gd2O3–MSN 
(e). Visualized particles had a uniform size distribution and showed no formation of aggregates. f Hydrody-
namic size distribution of PEG-TRITC–Gd2O3–MSN as measured by dynamic light scattering. The primary peak 
has a median particle size of 187.3 nm. Scale bars indicate 100 nm
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in tissue culture or in vivo, the fluorescence (FITC or TRITC) was measured using serial 
dilutions in a fluorimetric plate reader. In order to eliminate unbound fluorophores from 
the suspension, the particle suspensions were repeatedly rinsed in phosphate buffered 
saline and centrifuged until no detectable fluorescence was observed in the supernatant.
Labeling/flow cytometry
Particle uptake by TCC cells was determined by flow cytometry. GFP−/TRITC− cells 
were used to establish the threshold for detection (Fig. 2a) while the GFP+/TRITC− cells 
were used to confirm the efficiency of GFP transfection, which was found to be 99.8 % 
(Fig. 2b). In the final sample, 69.6 % of the cells were found to be GFP+/TRITC+ (Fig. 2c), 
with a wide range of levels of rhodamine fluorescence, indicating some cells picked up 
more MSN particles than others.
In vivo fluorescence
Implantation of PEG–TRITC–Gd2O3–MSN-labeled MB49-Luc+ and MB49-GFP+ cells 
was confirmed using in vivo luminescence and fluorescence (Fig. 3). Using the standard 
detection methods (luciferin luminescence or GFP fluorescence), the tumor was detect-
able within 6–8 days in vivo, consistent with previous results. Using the MSN for detec-
tion (TRITC fluorescence), the tumors were detectable in 1–4 days (Fig. 3b). The growth 
rate was consistent with that of unlabeled tumor cells, indicating that the particles are 
not inhibitive of tumor growth.
MRI imaging
We implemented two tumor labeling approaches, representing incremental stages mov-
ing towards translational significance. In the first, we labeled cells prior to implantation 
to determine the maximal MRI signal attainable. Subsequently, we implanted the tumor 
cells first, labeling them in vivo, to represent a clinically relevant scenario.
1. To determine the maximum MRI signal, MB49-Luc+ cells were labeled with PEG–
Gd2O3–TRITC–MSN prior to instillation in the bladder to obtain the best possible 
contrast in MRI. Tumors were also implanted in the left and right flank, using labeled 
and non-labeled cells, respectively, as controls. With T1-weighting, a hyperinten-
Fig. 2 Functionalized mesoporous silica nanoparticles (MSN) are taken up by mouse bladder cancer cells. 
Flow cytometry for MB49 bladder cancer cells exposed to 100 μg/mL PEG–Gd2O3–TRITC–MSN. a MB49-Luc
+ 
cells were used as negative controls for both GFP and TRITC. b MB49-GFP+ cells prior to labeling were 99.8 % 
GFP+/TRITC−. c After labeling, 69.6 % of the cells were found to be GFP+/TRITC+, with a range of levels of 
rhodamine fluorescence, indicating some cells picked up more MSN particles than others
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sity was observed for tumors comprised labeled cells relative to non-labeled cells 
(Fig. 4a). After segmentation, the normalized MRI values of labeled (161.2 ± 11.8) 
versus non-labeled (143.3  ±  12.9) flank tumors were compared using the TOST 
test for equivalency with a test margin of 0.05 and found to be non-equivalent at a 
significant (p < 0.0001) level (Fig. 4b). Further, the tumor instilled into the bladder 
(159.5 ± 12.8), also comprised MSN-labeled cells, was found to be equivalent to the 
flank tumor comprised labeled cells (p > 0.05) and non-equivalent to the tumor com-
prised non-labeled cells (p < 0.001). This initial test also confirmed that the process of 
labeling MB49 cells with MSN did not alter their ability to engraft, either subcutane-
ously or in the bladder. Three-dimensional rendering of the tumor shows infiltration 
of the bladder wall, potentially metastasizing to nearby tissues (Fig. 4c). This repre-
sents clinically important data for tumor staging.
2. To represent a more clinically relevant scenario, we subsequently injected MB49 
tumors to establish the tumor, then after 8  days we labeled in  vivo via intravesic-
ular instillation of colloidal PEG–Gd2O3–TRITC–MSN particles (1  mg MSN in 
50 μL PBS). MRI scans showed immediately before and 1 day after MSN addition 
to determine the qualitative effects of the MSN on tumor characterization as well as 
the quantitative changes in T1- and T2-weighted MRI signal for bladder tumor rela-
tive to normal bladder epithelium. A representative 2-D slice of T2-weighted MRI 
of the same tumor is shown before (Fig. 5a) and 24 h after (Fig. 5d) addition of MSN 
particles. Each pair of images is shown after normalization, using equivalent input–
output color maps. Additional 3-D renderings of the tumor in situ (Fig. 5b, e) and 
segmented (Fig. 5c, f ) reveal unique features within the tumor, including finger-like 
projections which have a different consistency than the bulk of the tumor and can be 
traced along the outer boundary. Quantitatively, the animals with tumors showed a 
Fig. 3 In vivo measurement of growth in tumors labeled with PEG–CF3–Gd2O3–TRITC–MSN. a IVIS imag-
ing of GFP and TRITC fluorescence in a mouse injected with labeled MB49-GFP+ cells. The top row indicates 
GFP signal arising from the cells. The day 1 signal is low because the number of implanted cells is small; 
when the tumor reaches a significant size, a large signal is detected. The second row shows the signal from 
PEG–CF3–Gd2O3–TRITC–MSN. The signal is detectable immediately, despite a small number of tumor cells 
implanted. MB49 cells engulf the particles where they remain in the cytoplasm. Following each mitotic event, 
the cytoplasm is split between the daughter cells, thus dividing the signal in half with each cellular division. 
In b, we confirm a relative and progressive attenuation of the TRITC signal. Taken together, the increase in 
GFP fluorescence as the tumor grows coincides with the diffusion of TRITC fluorescence. Thus, the labeling 
provides an additional level of early detection not found in unlabeled MB49 tumors
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much larger magnitude of change in normalized MRI value after administration of 
particles than the bladder walls of non-tumor, sham-injected negative control mice 
(Fig. 6). This result provides evidence that in vivo tumors take up MSN particles with 
a higher affinity than normal bladder epithelium. The projections were found to be 
considerably hypointense in these renderings of T2-weighted scans, indicative that in 
larger tumors, a subset of cells have an especially high affinity for the MSN.
Histological analyses
To validate and confirm MRI observations, we process tissues for histological evalua-
tion. The bladders were excised after the final MRI scans, re-scanned for whole tissue 
fluorescence signal using the IVIS system, and then serially sectioned. Gross anatomi-
cal observations using IVIS show, as expected, only the Luc+ tumor showing luciferase 
luminescence, while both the GFP+ and Luc+ tumor have positive fluorescence in the 
red channel, indicating retention of the PEG–Gd2O3–TRITC–MSN (Fig. 7). The finger-
like projections seen in MRI (Fig. 5f ) were observed to be regions of higher cell density/
faster growth (Fig. 5g), and are consistent with observations made of TCC in humans 
(Cheng et  al. 2009). Additionally, the fluorescence micrograph (Fig.  5h) corroborates 
the MRI scan, showing that these are the areas of greatest particle uptake. In both the 
T1- and T2-weighted MRI scans, we observed clear improvements in boundary deline-
ation. This allowed for the in vivo evaluation of features such as the bladder wall with a 
level of detail approaching that of histological sections (Fig. 8). Based on measurements 
collected from both MRI and histological sections, we calculated the thickness of the 
bladder wall to be approximately 1.00 mm, corresponding to 17 pixels at our achievable 
resolution.
This report documents the findings on an orthogonal mouse model, and the potential 
for translation to clinical use of a novel nanoparticle-based technology. This approach 
may improve diagnostic and potentially therapeutic outcomes in TCC of the bladder. We 
are unaware of clinically relevant gold standards to use for a comparative basis. Clinical 
Fig. 4 Optimal/maximum binding of MSN: bladder cancer cells were labeled (70 %) prior to injection into 
mouse and then MRI performed. a A pseudocolor slice of T1-weighted axial MRI data showing definite 
intensity difference 8 days post-injection between the two subcutaneous injections in the thigh (particle 
labeled cells in the left flank, L, and non-labeled cells in the right flank, R) as well as the tumor within the blad-
der (in situ) (T) and bladder wall (W). b The measured MRI values for each region shown. Error bars indicate 
standard deviation; * asterisk when compared using the two one-sided T-test of equivalence, the intensity of 
labeled tumor in the left flank and bladder were not equivalent to the non-labeled tumor and bladder wall 
(p < 0.0001). c A 3-D virtual cystoscopy rendering of the same tumor in (a) with the tumor identified by fuzzy 
C-means segmentation (red). Unique features: arrows indicate regions where the tumor has invaded the blad-
der wall, an important pathological milestone
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Fig. 5 Evaluation of increased contrast and histopatholgical benefits of our nanoparticle technology. MSN 
bind preferentially to bladder cancer cells relative to normal bladder epithelia in vivo as shown in a series 
of renderings of T2-weighted MRI scans acquired before (a–c) and after (d–f) intravesicular instillation of 
Gd2O3–TRITC–MSN. a and d 2-dimensional grayscale view, the tumor (T) is shown before and after injection 
of particles; note clear labeling of the tumor surface * asterisk. (b, e) 3-dimensional rendering provides further 
evidence of the particle distribution on the tumor surface. c, f Here the tumor is segmented and rendered 
with a pseudocolor map. Finger-like projections are revealed which are not observed before the injection of 
particles (c). Histology confirms anatomical observations and particle penetrations in the structures within 
the tumor: bright field (g) and fluorescent microscopy (h). Scale bars 1 mm (a–f); 250 μm (g, h)
Fig. 6 T1 and T2 signal changes specific to the in vivo bladder tumor as the result of particle injections. The 
normalized average MRI intensities of bladder tumor and normal (sham-injected, negative control) bladder 
wall were measured before and after administration of MSN. The result was an increase in apparent T1 inten-
sity and a decrease in T2 intensity in tumor bladders, compared with minimal change in the normal bladder 
wall (*−p < 0.0001)
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approaches include ImmunoCyt/uCyt™, a fluorescent test that uses three monoclonal 
antibodies (Vergara-Lluri et al. 2014), and UroVysion™, which is an in situ hybridization 
test using four different probes to different chromosomes (Seideman et al. 2015). We are 
aware of the benefits of Hexvix, or hexyl aminolevulinate, which is similar to a chemical 
found naturally in the body and contains porphyrins (Martoccia et al. 2014). The under-
lying principle of this approach is that cancer cells absorb this substance faster than 
healthy cells and turn fluorescent pink when the cystoscope light changes from white to 
blue. To date, we have not seen a report of cystoscopy-based approaches used in murine 
models.
Using the well-established MB49 murine line of bladder cancer cells, the uptake of our 
particles was measured in vitro, followed by non-invasive detection of labeled, implanted 
tumors in  vivo using magnetic resonance imaging. In a pre-clinical animal model for 
bladder cancer, free particles were instilled in bladders with pre-established tumors. We 
demonstrate that the localization of the particles highlighted to the tumor helped deline-
ate its edges and other features which were not otherwise detectable. We identified fin-
ger-like projections-areas which are consistent with the literature and are believed to be 
Fig. 7 IVIS images of ex vivo bladders under luciferase luminescence and DsRed fluorescence. Ten days 
after implantation of labeled MB49 cells, one mouse from each group was sacrificed and the bladders were 
excised along with the kidneys and portions of lung for comparison. Luminescence was only observed in 
the bladder of the mouse injected with MB49-Luc+ cells, while both the MB49-Luc+ and MB49-GFP+ tumors 
were positive for TRITC fluorescence, indicative of the retention of PEG–CF3–Gd2O3–TRITC–MSN
Fig. 8 Multimodal evaluation of bladder wall in a tumor model. a T2-weighted image of bladder wall. Blad-
der wall thickness (red line) was calculated to be ~1.00 mm or approximately 17 pixels. b Histological section 
of same bladder after excision. Bladder wall thickness was also measured to be ~1.00 mm. c The many folds 
of the bladder epithelium can also be visualized in 3-dimensions, as seen in this rendering (arrow)
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connective cellularized tissue (Cheng et  al. 2000). These tumor penetrating structures 
displayed a higher particle uptake than the surrounding tumor. It is tempting to envision 
the potential therapeutic applications of the particles as they are able to access the inner 
cellular components of the tumor.
Two major hindrances to the recovery and poor prognostics of this form of cancer is 
the delay in detection of the cancer and its subsequent propensity to rapidly metastasize 
to adjacent tissue (Faba et al. 2012; Kaufman 2006). Although TCC is among the most 
deadly forms of cancer, the methods for diagnosis, including fluorescent and colored 
dyes that “paint” the bladder wall and delineate the tumor for use with cystoscopic tech-
niques, however, are lacking in both depth of penetration and accuracy (Liu et al. 2012; 
Bryan et al. 2014). Because the depth of tumor penetration is difficult to grade through 
cystoscopic means alone, the bladder is often removed as a precautionary measure, to 
the severe detriment of quality of life for the patient (Kaufman et al. 2009; Dalbagni et al. 
2009; Gakis et al. 2013). Our results show a novel option based on a core of MSN for 
multimodal use in cancer diagnostics. In addition, the potential is clear for the material 
to be used therapeutically, as a carrier of anti-tumor agents. The engineered nanoparti-
cles are made to improve visualization of the tumor through T1- and T2-weighted com-
putational MRI techniques.
Using the well-established MB49 murine TCC line in culture, we found 69.6 % of cells 
to be labeled with our PEG–Gd2O3–TRITC–MSN, with most cells fluorescing between 
2 and 3 orders of magnitude above the detection threshold for the flow cytometry instru-
ment. The particles were well tolerated by the cells; viability of labeled cells remained 
high (over 90 %) as indicated by trypan blue exclusion dye measurement and by virtue of 
the successful engraftment of labeled tumor cells in vivo. The manner of uptake has not 
yet been characterized, though from the literature and our own observation it is most 
likely that particles are engulfed by phagocytosis. The uptake mechanism of similarly 
sized and functionalized MSN has been characterized by other groups as co-localized 
with endosomes (Slowing et al. 2006; Hsiao et al. 2008). These studies have examined the 
involvement of clathrin-coated pits, using inhibition of clathrin to show reduced uptake 
(Huang et al. 2005), and lysosomes, using fluorescent lysosomal tracking dyes (Slowing 
et al. 2006). Additional determination of uptake awaits future experimentation with spe-
cific cell signaling molecules on the MSN surface.
The current standard pre-clinical model for TCC is the mouse orthotopic model in 
which MB49 murine TCC cells are implanted onto a chemically disrupted bladder epi-
thelium (Luo et al. 2004). Although the model presents a number of advantages, i.e., it 
reliably creates tumors which closely mirror the histological picture of human TCC, 
we found that the tumor growth varies greatly depending on the quality of the chemi-
cal disruption and the number of cells that bind to it. In addition, the small size of this 
animal model does not lend itself to cystoscopy or other clinically relevant screening 
techniques. In this report, we show that by combining the animal model with the image 
improvement offered by our MSN, we can use small animals (mice) and create valu-
able virtual cystoscopy. Our early experiments involved labeling of cells with our par-
ticles prior to implantation in order to optimize our imaging parameters, and to show 
that labeled cells will engraft and grow in a similar manner to non-labeled tumor cells. 
Control injections of labeled and non-labeled cells implanted subcutaneously in either 
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thigh of the mouse showed similar growth characteristics, indicating that cell labeling 
alone did not adversely affect tumor growth or implantation. Importantly, our technol-
ogy allows for the non-invasive detection of histological features. Within the bladder, the 
tumor boundary was more easily delineated, and was observed to cross the bladder wall. 
These crucial data regarding depth of tumor penetration are impossible to obtain clini-
cally through cystoscopy alone ( Cheng et al. 2000, 2009; Mitra et al. 2012).
Our experimentation strategy was first to establish a bladder tumor model in which 
nanoparticles would be most visible and then refine our approach to develop a method 
with more clinical relevance where the tumor was initiated in the bladder, then followed 
by injection and binding in vivo of free MSN 8 days later. Interestingly, prior to the instil-
lation of particles, the MRI scan shows a very homogeneous tumor which reflects the 
uniformity of the MB49 cells in culture. Only after administration of particles are unique 
heterogeneities revealed, which are correlated histologically. This includes the forma-
tion of finger-like projections, forming largely around the boundaries of the bulk tumor. 
These regions appear to be more fibroblastic in morphology, with a denser matrix of 
connective tissue than the bulk tumor, as evidenced by the higher relative amount of 
eosin staining. Furthermore, these regions have a higher affinity for our MSN than the 
bulk tumor; this is consistent with our observations, and those of other groups, (Hsiao 
et  al. 2008; Selvan et  al. 2010) that MSN are readily engulfed by fibroblast cells. To 
the best of our knowledge, nothing is published regarding the heterogeneity of MB49 
tumors in  situ, though groups have reported the presence of finger-like projections in 
human clinical pathological specimens. (Cheng et al. 2000).
The typical clinical tool for bladder cancer diagnosis is white light or fluorescent cys-
toscopy, used in conjunction with a form of dye that improves definition of the tumor 
boundaries (Kriegmair et  al. 1994; Filbeck et  al. 2002; Joudi and Konety 2004). Clini-
cally, MRI virtual cystoscopy of the bladder is less commonly used, (Raza and Jhaveri 
2012) and although gadolinium-based contrast agents are sometimes administered 
intravenously prior to scanning, specific agents that bind tumors are not yet available. 
Our results indicate that intravesicular instillation of MSN particles improves differen-
tiation of the tumor in MRI; the signal obtained from normal bladder wall is unaffected 
by particle instillation, whereas the signal of the tumor increases under T1-weighted 
MRI, and decreases under T2-weighted MRI (Fig. 6). This is consistent with the accu-
mulation of gadolinium-based contrast agents in tumors, and corroborated by the dif-
ference observed in fluorescence signals from excised bladders of tumor and normal 
mice (Fig. 5). In normal bladder epithelia, the particles that were retained appeared to be 
discretized in macrophages, whereas the tumor tissue possessed a brighter, more wide-
spread fluorescence throughout, or in the case of more heterogeneous tumors, spread 
among a particular subpopulation of the tumor.
In this study, taking into account the consideration that clinical efficacy of using nan-
oparticles may be hindered or diminished due to bladder epithelium becoming hyper-
permeable in TCC bladders (Brown et  al. 1993; Gontero et  al. 2004). The immediate 
implications being that particles may bind to non-tumor regions in a cancerous bladder, 
thus leading to overestimation of the true tumor size. We showed that has not been the 
case in our study, as we clearly demonstrate that our particles have a predilection for 
Page 14 of 18Sweeney et al. Cancer Nano  (2016) 7:3 
cancerous tissue. Further improvement will have to wait for the development of specific 
targeting strategies.
With respect to image quality improvement, our current small animal scanner has a 
magnetic field of 4.7 T and is capable of in-plane image resolutions below 100 μm. At 
this resolution, we detected patterns in MRI corresponding to layers observed in his-
tological sections, and visualized folding patterns within the bladder 3-dimensionally 
(Fig. 8). With the advent of MRI systems with magnets as large as 7 T and more powerful 
gradient coils, both in small animal and clinical use, we anticipate an improvement in 
signal/contrast for the same MSN formulation.
Thus, there is a need to improve with higher-specificity molecules. In addition to 
advances in imaging technology, the obtained signal can be further improved by increas-
ing the specificity of the particles for bladder cancer cells. The particles presented thus 
far have not been functionalized for cell specificity; the specificity we observe is a result 
of exploiting the morphological differences between normal and tumor cells in the 
bladder. Whereas healthy/intact epithelium is defined by tight gap junctions and cell 
adhesion molecules only at the basement membrane, diseased (cancerous/inflamed) epi-
thelium divides rapidly, has looser gap junctions, and overexpresses adhesion molecules, 
such as EpCAM (Bryan et al. 2014; Kowalski et al. 2010) integrins, (Knowles et al. 2013) 
laminin, cadherins, (Gontero et al. 2004) and other surface molecules (Parker et al. 2005; 
Tagaya et al. 2014). Due to these features, diseased epithelium has a higher affinity for 
foreign objects than normal epithelia. To improve upon this, our colleagues have identi-
fied a short peptide sequence using a phage display library with a high affinity for a wide 
range of bladder cancer cells across multiple species including mouse, dog, and human, 
and with little affinity for normal bladder epithelia. We intend to enhance the specificity 
of our particles through their functionalization with this peptide. To that end, we have 
developed a new particle capable of binding proteins/peptides through coupling chemis-
try (Hermanson 2008).
An additional desirable property of MSN particles which was not directly addressed 
in this study would be to have uptake and delivery of soluble materials within their 
porous structure. Many have successfully demonstrated delivery of bioactive agents 
in vitro using MSN (Giri et al. 2005; Gruenhagen et al. 2005; Slowing et al. 2007; Chen 
et  al. 2010). The increased complexity of delivery in vivo makes it a more challenging 
scenario (Chan and Lin 2015; Wang et al. 2015). However, if some of these challenges 
can be overcome in the harsh chemical environment of the bladder, cancer treatment 
can be vastly improved. Whereas most chemotherapeutics are quickly eliminated from 
the bladder via urination (Grabnar et  al. 2006; GuhaSarkar and Banerjee 2010), parti-
cles loaded with chemotherapeutics and retained by tumor cells will remain in the blad-
der for a longer time. Similarly, BCG immunotherapy can be improved through longer 
retention times, thus improving the depth of drug delivery, rather than simply removing 
the outermost cells a few layers at a time as current therapies tend to do (Kaufman 2006; 
Kim and Steinberg 2001).
Conclusions
This study represents a unique example of the synergistic use of MRI, nanoparti-
cles and computational imaging to visualize TCC in a mouse model in 3 dimensions, 
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as a prototype for similar use in human TCC. Our approach allows for a significantly 
improved detailed window into the pathogenesis of the tumor, including invasion of the 
bladder wall and heterogeneities within the tumor. These pathological hallmarks are fre-
quently observed in human-excised tissue. Currently, MRI 3-D reconstruction of the 
bladder is less common than traditional cystoscopic evaluation despite the fact that it is 
less invasive than cystoscopy, and important observations, including tumor staging, may 
be missed. The challenge in translating this technology to humans, where the tumor will 
be much smaller relative to the entire bladder at the time of imaging, will be improving 
the specificity for TCC to obtain the strongest signal possible. However, we predict that 
through additional research, a combination of MRI and fluorescent cystoscopy aided 
by MSN will make it possible to more accurately assess human TCC, and ultimately, if 
caught at a sufficiently early stage, improve patient prognosis.
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